Estaphan Suzanne, Curpăn Alexandrina-Stefania, Khalifa Dalia, Rashed Laila, Ciobica Andrei, Cantemir Adrian, Ciobica Alin, Trus Constantin, Ali Mahmoud, ShamsEldeen Asmaa
Physiology Department, Faculty of Medicine, Cairo University, Cairo 12613, Egypt.
ANU Medical School, Australian National University, Canberra 2605, Australia.
Brain Sci. 2021 Jul 11;11(7):917. doi: 10.3390/brainsci11070917.
While animal models for schizophrenia, ranging from pharmacological models to lesions and genetic models, are available, they usually mimic only the positive symptoms of this disorder. Identifying a feasible model of chronic schizophrenia would be valuable for studying the possible underlying mechanism and to investigate emerging treatments. Our hypothesis starts from the observation that combining ketamine with isolation could result in long-lasting neuro-psychological deficits and schizophrenia-like features; thus, it could probably be used as the first model of chronic schizophrenia that emphasizes the characteristic of having a multifactorial etiology. By the means of this study, we investigated the effects of ketamine administration combined with isolation in inducing schizophrenia-like symptoms in male albino rats and the brain reactive oxygen species levels. Our results showed that the number of lines crossings in the open field test, the number of open arm entries in the elevated plus maze, and the spontaneous alternations percentage in the Y-maze were significantly lower in the ketamine + isolation group compared to both the control and ketamine + social housing group ( < 0.05). Furthermore, the ketamine + isolation intervention significantly increased the MDA levels and decreased the GPx levels both in the hippocampus and the cortex of the rats. In addition, our premise of creating a model capable of exhibiting both positive and negative symptoms of schizophrenia was also based on adding the aripiprazole treatment to a group of rats. Therefore, we compared the ketamine + social isolation group with the ketamine + social isolation + aripiprazole group in order to attempt to discover if the antipsychotic drug would significantly decrease the potential positive schizophrenia-like symptoms induced by social isolation and ketamine. Given that we obtained significant results, we cautiously presume that this might be an important step in developing our animal model capable of illustrating both positive and negative symptoms of schizophrenia. This study could be a first step towards the creation of a complex animal model capable of exhibiting the multifactorial origin and manifestation of schizophrenia.
虽然有从药理学模型到损伤模型和遗传模型等多种精神分裂症动物模型,但它们通常仅模拟该疾病的阳性症状。确定一种可行的慢性精神分裂症模型对于研究潜在机制和探索新出现的治疗方法将具有重要价值。我们的假设基于这样的观察结果:将氯胺酮与隔离相结合可能导致长期的神经心理缺陷和精神分裂症样特征;因此,它可能被用作第一个强调具有多因素病因特征的慢性精神分裂症模型。通过本研究,我们调查了氯胺酮给药联合隔离对雄性白化大鼠诱导精神分裂症样症状的影响以及大脑活性氧水平。我们的结果表明,与对照组和氯胺酮 + 群居组相比,氯胺酮 + 隔离组在旷场试验中的穿越线数、高架十字迷宫中的进入开放臂次数以及Y迷宫中的自发交替百分比均显著降低(<0.05)。此外,氯胺酮 + 隔离干预显著增加了大鼠海马和皮层中的丙二醛水平,并降低了谷胱甘肽过氧化物酶水平。此外,我们创建一个能够表现出精神分裂症阳性和阴性症状的模型的前提还基于对一组大鼠添加阿立哌唑治疗。因此,我们将氯胺酮 + 社会隔离组与氯胺酮 + 社会隔离 + 阿立哌唑组进行比较,以试图发现抗精神病药物是否会显著降低由社会隔离和氯胺酮诱导的潜在精神分裂症样阳性症状。鉴于我们获得了显著结果,我们谨慎推测这可能是开发能够说明精神分裂症阳性和阴性症状的动物模型的重要一步。这项研究可能是朝着创建一个能够展示精神分裂症多因素起源和表现的复杂动物模型迈出的第一步。